Qure.ai Technologies Inc.

AI for accessible, affordable & timely care across the globe

Qure.ai, a leading technology firm, uses deep learning and Artificial Intelligence (AI) tools to make healthcare more accessible and affordable to patients around the world. Our solutions automatically interpret radiology images and primarily focus on the early diagnosis of pulmonary diseases and traumatic brain injuries. The technology improves the accuracy and efficiency of the radiology function in traditional hospital settings and smaller, remote medical care teams with limited resources and capabilities. Founded in 2016, our CE and FDA-cleared AI tools are used in over 500 healthcare facilities across 50 countries and have impacted more than 10 million lives. We have 32 collective peer-reviewed journals, including the industry’s most prestigious outlet— The Lancet. We also have five patents. Our leading product, qXR, aids in the detection of multiple abnormal findings on a chest X-ray in less than 1 minute. qXR can flag abnormal scans from normal and detect abnormalities in the lungs, pleura, mediastinum, bones, diaphragm, and heart. It can also aid clinicians with assessment of placement of devices and measurement of the distance from anatomical landmarks in the thorax. We work with several governments, and our ongoing partnerships with pharmaceutical companies such as Viatris and AstraZeneca have resulted in ground-breaking work on tuberculosis and lung cancer with qXR. Qure.ai is proudly backed by Sequoia Capital and Mass Mutual Ventures.